CD8A and neoplasm: A recombinant chimeric protein (SA-4-1BBL) containing the extracellular domains of murine 4-1BBL fused to a modified form of core streptavidin has generated robust CD8+ T effector and memory responses in several preclinical tumor models as an adjuvant with tumor associated antigen vaccines [94–97].